Literature DB >> 25114873

The TRHR Gene Is Associated with Hypothalamo-Pituitary Sensitivity to Levothyroxine.

Giulia Brigante1, Giorgia Spaggiari1, Daniele Santi1, Katia Cioni1, Valentina Gnarini1, Chiara Diazzi1, Elisa Pignatti2, Livio Casarini2, Marco Marino2, Frank Tüttelmann3, Cesare Carani1, Manuela Simoni4.   

Abstract

BACKGROUND: Thyroidectomized patients need variable doses of levothyroxine (LT4) to obtain target thyroid-stimulating hormone (TSH) levels. Individual feedback set-points have been hypothesized and the influence of several genes in the regulation of the pituitary-thyroid axis has been demonstrated.
OBJECTIVES: We hypothesized that genetic variants of the TRHR gene could be associated with a different hypothalamo-pituitary sensitivity to thyroid hormone feedback.
METHODS: We retrospectively analyzed 84 thyroidectomized patients with no residual thyroid function and undetectable thyroglobulin levels. Patients were evaluated under LT4 resulting in TSH levels detectable but <0.5 μIU/ml. The two SNPs rs3134105 and rs3110040 were identified as informative markers of the TRHR gene. Genotyping was performed using high-resolution melting technology. Genotype distribution was compared between the patients and 99 euthyroid controls.
RESULTS: The selected SNPs were in linkage disequilibrium and only rs3134105 was further considered. A significant difference between the three possible genotypes for rs3134105 was found for TSH (p = 0.04) and free thyroxine (fT4)/TSH ratio (p = 0.02). Moreover, despite similar serum concentrations of free triiodothyronine (fT3) and fT4, carriers of at least one A allele of rs3134105 had significantly lower serum TSH levels (p = 0.01) as well as higher fT3/TSH (p = 0.01) and fT4/TSH ratios (p < 0.01).
CONCLUSIONS: We demonstrated an association between serum TSH levels and discrete alleles of the TRHR gene in totally thyroidectomized patients under LT4 therapy. Therefore, the TRHR gene seems to be a determinant of hypothalamo-pituitary sensitivity to LT4.

Entities:  

Keywords:  Hypothalamo-pituitary sensitivity; TRHR; TSH suppression

Year:  2014        PMID: 25114873      PMCID: PMC4109513          DOI: 10.1159/000358590

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN: 2235-0640


  35 in total

Review 1.  Extrahypothalamic thyrotropin releasing hormone (TRH) -- its distribution and its functions.

Authors:  J E Morley
Journal:  Life Sci       Date:  1979-10-29       Impact factor: 5.037

Review 2.  Thyroid-hormone therapy and thyroid cancer: a reassessment.

Authors:  Bernadette Biondi; Sebastiano Filetti; Martin Schlumberger
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2005-11

3.  Optimising workflow in andrology: a new electronic patient record and database.

Authors:  Frank Tüttelmann; C Marc Luetjens; Eberhard Nieschlag
Journal:  Asian J Androl       Date:  2006-03       Impact factor: 3.285

Review 4.  Deiodinases: implications of the local control of thyroid hormone action.

Authors:  Antonio C Bianco; Brian W Kim
Journal:  J Clin Invest       Date:  2006-10       Impact factor: 14.808

5.  Variations in adequate levothyroxine replacement therapy in patients with different causes of hypothyroidism.

Authors:  M B Gordon; M S Gordon
Journal:  Endocr Pract       Date:  1999 Sep-Oct       Impact factor: 3.443

6.  Pseudomalabsorption of levothyroxine.

Authors:  K B Ain; S Refetoff; H G Fein; B D Weintraub
Journal:  JAMA       Date:  1991-10-16       Impact factor: 56.272

7.  Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects.

Authors:  Robin P Peeters; Hans van Toor; Willem Klootwijk; Yolanda B de Rijke; George G J M Kuiper; Andre G Uitterlinden; Theo J Visser
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

Review 8.  Levothyroxine therapy in patients with thyroid disease.

Authors:  S J Mandel; G A Brent; P R Larsen
Journal:  Ann Intern Med       Date:  1993-09-15       Impact factor: 25.391

9.  Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients.

Authors:  Massimo Torlontano; Cosimo Durante; Isabella Torrente; Umberto Crocetti; Giovanni Augello; Giuseppe Ronga; Teresa Montesano; Laura Travascio; Antonella Verrienti; Rocco Bruno; Stefano Santini; Palmina D'Arcangelo; Bruno Dallapiccola; Sebastiano Filetti; Vincenzo Trischitta
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

10.  Aging and the thyroid. Decreased requirement for thyroid hormone in older hypothyroid patients.

Authors:  C T Sawin; T Herman; M E Molitch; M H London; S M Kramer
Journal:  Am J Med       Date:  1983-08       Impact factor: 4.965

View more
  2 in total

1.  The optimal dosing scheme for levothyroxine after thyroidectomy: A comprehensive comparison and evaluation.

Authors:  Nick A Zaborek; Andy Cheng; Joseph R Imbus; Kristin L Long; Susan C Pitt; Rebecca S Sippel; David F Schneider
Journal:  Surgery       Date:  2018-11-06       Impact factor: 3.982

2.  Natural Autoimmunity to the Thyroid Hormone Monocarboxylate Transporters MCT8 and MCT10.

Authors:  Theresa Porst; Jörg Johannes; Hans Gluschke; Richard Köhler; Sebastian Mehl; Peter Kühnen; Kostja Renko; Waldemar B Minich; Susanna Wiegand; Lutz Schomburg
Journal:  Biomedicines       Date:  2021-04-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.